Cannabinoid Hyperemesis Syndrome in Adolescents: Diagnosis and Treatment Guide

The best current evidence for treating acute pediatric cannabinoid hyperemesis syndrome suggests IV rehydration followed by low-dose haloperidol, with complete cannabis cessation as the only long-term solution.

Lonsdale, Hannah et al.·Current opinion in pediatrics·2022·Moderate EvidenceNarrative Review
RTHC-04018Narrative ReviewModerate Evidence2022RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Narrative Review
Evidence
Moderate Evidence
Sample
Not reported

What This Study Found

Current best evidence recommends IV rehydration and electrolyte correction, followed by haloperidol 0.05 mg/kg with or without a benzodiazepine for acute pediatric CHS. The only effective long-term treatment remains complete cessation of cannabinoid use.

Key Numbers

Haloperidol dose: 0.05 mg/kg IV; presenting features: cyclical nausea, emesis, abdominal pain, hot shower relief

How They Did This

Narrative review of current literature on adolescent CHS, covering diagnosis, pathophysiology, and treatment evidence.

Why This Research Matters

CHS prevalence in adolescents continues to grow as cannabis becomes more accessible and potent. Clinicians need practical guidance because high-quality treatment evidence specific to pediatric populations is lacking.

The Bigger Picture

As adolescent cannabis use patterns evolve toward higher-potency products and more frequent use, CHS is likely to become an increasingly common pediatric emergency presentation.

What This Study Doesn't Tell Us

High-quality treatment evidence for adolescent CHS remains lacking. Recommendations are based on limited data extrapolated partly from adult studies.

Questions This Raises

  • ?Are there pharmacological treatments that could prevent CHS relapse in adolescents who cannot achieve cessation?
  • ?Does the potency of cannabis products influence CHS severity in young people?

Trust & Context

Key Stat:
Haloperidol 0.05 mg/kg recommended for acute treatment
Evidence Grade:
Narrative review providing practical guidance, but based on limited pediatric-specific evidence.
Study Age:
Published in 2022
Original Title:
Paediatric cannabinoid hyperemesis.
Published In:
Current opinion in pediatrics, 34(5), 510-515 (2022)
Database ID:
RTHC-04018

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study

Summarizes existing research without a strict systematic method.

What do these levels mean? →

Frequently Asked Questions

How is cannabinoid hyperemesis syndrome treated in adolescents?

Current best evidence suggests IV rehydration, electrolyte correction, and haloperidol 0.05 mg/kg with or without a benzodiazepine. Complete cessation of cannabis use is the only known long-term treatment.

How do you diagnose CHS in teenagers?

The key features are cyclical nausea, vomiting, and abdominal pain in the context of chronic cannabis use, with symptom relief from hot showers being a characteristic finding.

Read More on RethinkTHC

Cite This Study

RTHC-04018·https://rethinkthc.com/research/RTHC-04018

APA

Lonsdale, Hannah; Wilsey, Michael J. (2022). Paediatric cannabinoid hyperemesis.. Current opinion in pediatrics, 34(5), 510-515. https://doi.org/10.1097/MOP.0000000000001157

MLA

Lonsdale, Hannah, et al. "Paediatric cannabinoid hyperemesis.." Current opinion in pediatrics, 2022. https://doi.org/10.1097/MOP.0000000000001157

RethinkTHC

RethinkTHC Research Database. "Paediatric cannabinoid hyperemesis." RTHC-04018. Retrieved from https://rethinkthc.com/research/lonsdale-2022-paediatric-cannabinoid-hyperemesis

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.